Could a JAK inhibitor improve stem cell transplant success in myelofibrosis?
NCT ID NCT03427866
First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether giving ruxolitinib (Jakafi) before, during, and after a stem cell transplant can improve outcomes for people with myelofibrosis. The study includes patients with intermediate-2 or high-risk disease, or intermediate-1 with additional risk factors. The main goal is to see if this approach increases the number of patients who survive one year without graft-versus-host disease or relapse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ruxolitinib (Jakafi)
- What this could lead to
- If successful, this approach could reduce the risk of graft-versus-host disease and relapse after stem cell transplant for myelofibrosis.
- What could go wrong
- This is a phase 2 trial with a small number of participants, so results may not apply broadly. Ruxolitinib can cause side effects like low blood counts and infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
The Ohio State University Wexner Medical Center
Columbus, Ohio, 43210, United States
-
Vanderbilt University
Nashville, Tennessee, 37235, United States
-
Washington University
St Louis, Missouri, 63130, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug free myelofibrosis patients from frequent blood transfusions?
- Heart safety check for new myelofibrosis drug in healthy volunteers
- Targeted drug aims to stop blood cancer return after transplant
- New transplant recipe aims to tame Graft-Versus-Host disease
- New drug candidate targets Hard-to-Treat blood cancers
- New drug combo aims to make stem cell transplants safer for blood cancer patients